Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Canadian Veteran Receives Approval for APEX’s Psilocybin Therapy Through Health Canada’s Special Access Program

Canadian Veteran Receives Approval for APEX’s Psilocybin Therapy Through Health Canada’s Special Access Program

  • Post published:September 27, 2023
  • Post category:Press Release
Read more about the article Apex Labs announces the appointment of Chief Medical Officer & Chief Commercial Officer

Apex Labs announces the appointment of Chief Medical Officer & Chief Commercial Officer

  • Post published:August 10, 2023
  • Post category:Press Release
Read more about the article Apex Labs Receives Approval for US-Based Secondary GMP Psilocybin Supplier by Health Canada


USA – English





USA – English

Apex Labs Receives Approval for US-Based Secondary GMP Psilocybin Supplier by Health Canada USA – English USA – English

  • Post published:June 9, 2023
  • Post category:Press Release
Read more about the article Apex Labs Granted Approval for 160 Patient Macrodose Multi-Dose Psilocybin Clinical Trial by Health Canada

Apex Labs Granted Approval for 160 Patient Macrodose Multi-Dose Psilocybin Clinical Trial by Health Canada

  • Post published:April 20, 2023
  • Post category:Press Release
Read more about the article Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial

Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial

  • Post published:March 29, 2023
  • Post category:Press Release
Read more about the article Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical Trial

Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical Trial

  • Post published:February 1, 2023
  • Post category:Press Release
Read more about the article Apex Labs Granted Approval for North America’s First Take Home Psilocybin Clinical Trial

Apex Labs Granted Approval for North America’s First Take Home Psilocybin Clinical Trial

  • Post published:November 1, 2022
  • Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More